Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.08
-2.08 (-18.64%)
At close: Nov 13, 2026, 4:00 PM EST
9.02
-0.06 (-0.66%)
Pre-market: Nov 16, 2026, 7:09 AM EST
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $37.76M in the quarter ending September 30, 2026, with 44.86% growth. This brings the company's total for the last twelve months to $147.76M, up 75.10% year-over-year. In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth. That makes Zevra Therapeutics the 19,753rd largest company in the world by revenue and 3,058th in the United States.
Revenue (ttm)
$147.76M
Revenue Growth
+75.10%
P/S Ratio
3.66
Revenue / Employee
$2,422,361
Employees
61
Market Cap
540.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 163.30M |
| REGENXBIO | 153.91M |
| Orchestra BioMed Holdings | 31.21M |
| Crescent Biopharma | 15.00M |
| Capricor Therapeutics | 11.13M |
| Surrozen | 10.53M |
| Neurogene | 925.00K |
| Entera Bio | 42.00K |
ZVRA News
- 2 minutes ago - Zevra Therapeutics price target lowered to $18 from $23 at Guggenheim - TheFly
- 3 days ago - Zevra reports European negative opinion on MAA for arimoclomol - TheFly
- 3 days ago - Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union - GlobeNewsWire
- 12 days ago - Zevra Therapeutics reports Q3 EPS 26c, consensus 18c - TheFly
- 12 days ago - Zevra Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 12 days ago - Zevra Therapeutics Earnings release: Q3 2026 - Filings
- 12 days ago - Zevra Therapeutics Quarterly report: Q3 2026 - Filings
- 12 days ago - Zevra Reports Third Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire